Close Menu

NEW YORK – Bayer said on Tuesday that it will pay Systems Oncology $25 million upfront for rights to a compound in preclinical development for estrogen receptor (ER)-positive, metastatic breast cancer. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.